Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
03 sept. 2024 07h00 HE
|
Amphista Therapeutics
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
03 sept. 2024 03h00 HE
|
Amphista Therapeutics
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
23 mai 2024 07h00 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24 janv. 2024 07h00 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24 janv. 2024 03h00 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
26 sept. 2023 09h30 HE
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or...